CRXT · Clarus Therapeutics Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $6.37M | - |
| Cost of Revenue | $8.69M | - |
| Gross Profit | ($2.32M) | - |
| R&D | $2.40M | - |
| SG&A | - | - |
| Total Operating Expenses | $44.86M | - |
| D&A | $18.0K | - |
| Operating Income | $4.34M | - |
| Interest Expense | $15.39M | - |
| Income Tax | $0 | - |
| Net Income | $4.34M | - |
| EPS - Basic | $0.00 | - |
| EPS - Diluted | ($8.20) | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Cash & Equivalents | $26.41M | $655.4K |
| Accounts Receivable | $6.34M | - |
| Inventory | $14.21M | - |
| Accounts Payable | $13.95M | $178.6K |
| Current Assets | $51.64M | $823.5K |
| Total Assets | $51.71M | $59.47M |
| Current Liabilities | $66.06M | $420.8K |
| Long-term Debt | - | - |
| Total Liabilities | $67.63M | $19.13M |
| Stockholders' Equity | ($316.27M) | $5.00M |
| Retained Earnings | ($321.65M) | ($4.72M) |
Cash Flow
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Operating Cash Flow | ($41.58M) | - |
| Investing Cash Flow | ($63.0K) | - |
| Financing Cash Flow | $47.22M | - |
| CapEx | $63.0K | - |
| Free Cash Flow | ($41.64M) | - |
Ratios
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Profitability | ||
| Gross margin | -36.4% | - |
| Operating margin | 68.2% | - |
| EBITDA margin | 68.5% | - |
| Net margin | 68.2% | - |
| Free cash flow margin | -653.8% | - |
| FCF / Net income | -9.58 | - |
| R&D / Revenue | 37.7% | - |
| SG&A / Revenue | - | - |
| Effective tax rate | 0.0% | - |
| Return on assets | 8.4% | - |
| Return on equity | -1.4% | - |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 0.78 | 1.96 |
| Quick ratio | 0.57 | 1.96 |
| Cash ratio | 0.40 | 1.56 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | 0.3x | - |
| Equity multiplier | -0.16 | 11.89 |
| Liabilities / Assets | 1.31 | 0.32 |
| Efficiency | ||
| Asset turnover | 0.12 | - |
| Inventory turnover | 0.61 | - |
| Days sales outstanding | 363d | - |
| Days inventory outstanding | 597d | - |
| Days payable outstanding | 586d | - |
| Cash conversion cycle | 375d | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | - | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | - | - |
| Net income growth (YoY) | - | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | - | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | - | - |
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-7.05
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✓Net income positive
- ✗Operating cash flow positive
- -ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Clarus Therapeutics Holdings against the 5 most active filers in the same SIC group.